SOCS-6 Inhibitors
Suppressor of cytokine signaling 6 (SOCS-6) is a crucial negative regulator of cytokine signaling pathways, functioning to dampen excessive immune responses and maintain immune homeostasis. SOCS-6 belongs to the suppressor of cytokine signaling (SOCS) protein family, which comprises intracellular proteins that act as feedback inhibitors of cytokine receptor signaling. Specifically, SOCS-6 exerts its inhibitory effects by interacting with cytokine receptors and downstream signaling molecules, such as Janus kinases (JAKs) and signal transducer and activator of transcription (STAT) proteins. Through its N-terminal region, SOCS-6 binds to phosphorylated tyrosine residues on cytokine receptors, leading to the recruitment of components of the ubiquitin-proteasome system for receptor degradation. This mechanism effectively attenuates cytokine-induced signaling cascades, preventing excessive immune cell activation and inflammation. Moreover, SOCS-6 can also modulate cytokine signaling by acting as a scaffold protein, facilitating the assembly of protein complexes that regulate various cellular processes, including cell proliferation, differentiation, and immune responses.
Inhibition of SOCS-6 activity represents a potential strategy to enhance cytokine signaling and promote immune responses under conditions of immunosuppression or immune evasion. Several mechanisms can disrupt SOCS-6 function, including interference with its protein-protein interactions, post-translational modifications, or subcellular localization. Small molecules or peptides that target the interaction interface between SOCS-6 and its binding partners, such as cytokine receptors or signaling proteins, can competitively inhibit SOCS-6 binding, thereby preventing its inhibitory effects on cytokine signaling. Additionally, compounds that interfere with the post-translational modifications or cellular localization of SOCS-6 may also disrupt its regulatory function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin is a natural compound found in turmeric. It inhibits SOCS-6 indirectly by modulating the JAK/STAT pathway. Curcumin has been shown to suppress JAK/STAT signaling, impacting SOCS-6 expression and activity. It downregulates the transcription of SOCS-6 by interfering with the activation of JAKs and subsequently STATs, leading to reduced SOCS-6-mediated negative feedback on cytokine signaling pathways. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol is a synthetic flavone derivative with cyclin-dependent kinase (CDK) inhibitory properties. It indirectly inhibits SOCS-6 by affecting the cell cycle. By suppressing CDK activity, flavopiridol modulates downstream signaling pathways, including those involving SOCS-6. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib is a JAK1/JAK2 inhibitor studied in the research of myelofibrosis. It directly inhibits SOCS-6 by targeting the JAK/STAT pathway. Ruxolitinib blocks JAK1 and JAK2, leading to decreased phosphorylation of STATs and subsequent downregulation of SOCS-6. This direct inhibition disrupts the negative feedback loop mediated by SOCS-6, allowing for prolonged and enhanced cytokine signaling. | ||||||
Stat3 Inhibitor III, WP1066 | 857064-38-1 | sc-203282 | 10 mg | $132.00 | 72 | |
WP1066 is a small molecule that inhibits STAT3 phosphorylation. It indirectly inhibits SOCS-6 by modulating the JAK/STAT pathway. By preventing STAT3 activation, WP1066 impacts downstream signaling events, including those involving SOCS-6. The inhibition of STAT3 phosphorylation by WP1066 disrupts the feedback control exerted by SOCS-6 on JAK/STAT signaling, enhancing the cellular responsiveness to cytokines. | ||||||
AZD1480 | 935666-88-9 | sc-364735 sc-364735A | 5 mg 50 mg | $124.00 $1072.00 | 11 | |
AZD1480 is an inhibitor of JAK1 and JAK2 kinases. It directly inhibits SOCS-6 by targeting the JAK/STAT pathway. AZD1480 suppresses the phosphorylation of STATs by inhibiting JAK1 and JAK2, resulting in reduced SOCS-6 expression. This direct inhibition disrupts the negative feedback loop mediated by SOCS-6, allowing for prolonged and enhanced cytokine signaling in cells. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
Tyrphostin B42 (AG490) is a JAK2 inhibitor that directly inhibits SOCS-6 by targeting the JAK/STAT pathway. By specifically inhibiting JAK2, AG490 disrupts the phosphorylation of STATs and, consequently, downregulates SOCS-6 expression. This direct interference disrupts the negative feedback loop mediated by SOCS-6, promoting sustained JAK/STAT signaling in response to cytokines. | ||||||
Piperlongumine | 20069-09-4 | sc-364128 | 10 mg | $107.00 | ||
Piperlongumine is a natural alkaloid with anti-inflammatory properties. It indirectly inhibits SOCS-6 by modulating the NF-κB pathway. Piperlongumine has been shown to suppress NF-κB activation, impacting SOCS-6 expression and activity. By downregulating NF-κB, piperlongumine influences the transcriptional control of SOCS-6, providing an indirect mechanism for attenuating the inhibitory function of SOCS-6 on cytokine signaling. | ||||||
Cryptotanshinone | 35825-57-1 | sc-280649 | 10 mg | $119.00 | 1 | |
Cryptotanshinone is a natural compound with anti-inflammatory effects. It indirectly inhibits SOCS-6 by modulating the NF-κB pathway. Cryptotanshinone suppresses NF-κB activation, impacting SOCS-6 expression and activity. By downregulating NF-κB, cryptotanshinone influences the transcriptional control of SOCS-6, providing an indirect mechanism for attenuating the inhibitory function of SOCS-6 on cytokine signaling. | ||||||
JAK Inhibitor I | 457081-03-7 | sc-204021 sc-204021A | 500 µg 1 mg | $156.00 $339.00 | 59 | |
JAK Inhibitor I is a pan-JAK inhibitor that directly inhibits SOCS-6 by targeting the JAK/STAT pathway. By inhibiting multiple JAK isoforms, JAK Inhibitor I disrupts the phosphorylation of STATs, leading to reduced SOCS-6 expression. This direct interference disrupts the negative feedback loop mediated by SOCS-6, promoting sustained JAK/STAT signaling in response to cytokines. | ||||||
Stat3 Inhibitor VI, S3I-201 | 501919-59-1 | sc-204304 | 10 mg | $151.00 | 104 | |
S3I-201 is a selective STAT3 inhibitor. It indirectly inhibits SOCS-6 by modulating the JAK/STAT pathway. By suppressing STAT3 activation, S3I-201 impacts downstream signaling events, including those involving SOCS-6. The inhibition of STAT3 phosphorylation by S3I-201 disrupts the feedback control exerted by SOCS-6 on JAK/STAT signaling, enhancing the cellular responsiveness to cytokines. | ||||||